Healthcare
Phio Pharmaceuticals Corp.(PHIO)
Live Price
Offline$1.03
-4.63% today
1Y Change
-49.54%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -59.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phio Pharmaceuticals Corp. (PHIO) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.03 and down 49.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -59.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -59.3%, free cash flow -12.3% with operating margin 0.0% and ROIC -43.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -59.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +0.0% | +1.8% | โ |
2026 Mar 5, 2026 | +55.9% | -0.9% | +6.8% | +9.4% |
2025 Nov 13, 2025 | +2.2% | -9.1% | -16.8% | -21.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHIO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHIO Max Drawdown
-68.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHIO and SPY.
Company Overview
Phio Pharmaceuticals Corp.
NASDAQ Capital Market
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
- Leadership
- Robert J. Bitterman
- IPO Date
- May 10, 2012
- Employees
- 5
- Street Address
- 257 Simarano Drive
- Mailing
- Marlborough, MA, 01752
- Region
- Marlborough, MA, US
- Reporting Currency
- USD
- Investor Line
- 508 767 3861
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.9
- Price/Sales
- โ
- Price/Book
- 0.7
Growth
- Revenue
- 0.0%
- EPS
- -59.3%
- Free Cash Flow
- -12.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -66.6%
- ROIC
- -43.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 49.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.